消癌解毒方联合DCF方案治疗进展期胃癌  

Treatment of Advanced Gastric Carcinoma with Xiaoai Jiedu Prescription Combined with DCF Regimen

作　　者：何群英[1] 王锐[1] 孙喜才[1] HE Qunying;WANG Rui;SUN Xicai(The first Hospital Affiliated to Medical College of Xi'an Jiao Tong University,Xizan Shaanxi China 710061)

机构地区：[1]西安交通大学医学院第一附属医院,陕西西安710061

出　　处：《中医学报》2019年第2期343-347,共5页Acta Chinese Medicine

基　　金：国家自然科学基金项目(30381356)

摘　　要：目的:探讨消癌解毒方联合DCF方案治疗进展期胃癌的临床疗效。方法:将65例进展期胃癌患者按随机数字表法分为两组。对照组32例予以单一DCF方案治疗,观察组33例给予DCF方案+消癌解毒方治疗,观察比较两组客观病灶疗效、中医证候疗效及T淋巴细胞亚群(CD_4^+、CD_8^+、CD_3^+)、自然杀伤细胞(natural killer cell,NK)活性变化情况,并统计两组不良反应发生情况及社会、情绪、角色及躯体、认知各功能生存质量评分。结果:观察组缓解率为66.67%,对照组为65.63%,两组比较,差异无统计学意义(P>0.05);观察组中医证候有效率为87.88%,高于对照组59.38%,差异具有统计学意义(P<0.05);观察组治疗6周后CD_4^+、CD_3^+、NK活性均优于对照组,差异具有统计学意义(P<0.05);观察组不良反应发生率为18.18%,对照组为15.63%,两组比较,差异无统计学意义(P>0.05);治疗6周后观察组社会、情绪、角色及躯体、认知各功能评分均高于对照组,差异具有统计学意义(P<0.05)。结论:消癌解毒方联合DCF方案治疗进展期胃癌效果显著,安全性高,可改善T淋巴细胞亚群及NK活性,提高患者生命质量。Objective:To investigate the clinical effects of Xiaoai Jiedu Decoction combined with DCF regimen in the treatment of advanced gastric cancer.Methods:Sixty-five patients with advanced gastric cancer were randomly divided into two groups according to the random number table method.32 patients in the control group were treated with a single DCF regimen,and 33 patients in the observation group were treated with DCF regimen+Xiaoai Jiedu Decoction.The effects of objective lesions,TCM syndromes and T lymphocyte subsets(CD4+,CD8+,CD3+) were compared.The changes of natural killer cell(NK) activity,and the incidence of adverse reactions and social,emotional,role and physical and life quality scores of the two groups were counted.Results:The remission rate was 66.67% in the observation group and 65.63% in the control group.There was no significant difference between the two groups(P>0.05).The effective rate of TCM syndrome treatment in the observation group was 87.88%,which was higher than that of the control group(59.38%).The difference was statistically significant(P<0.05).The activity of CD4+,CD3+ and NK in the observation group was higher than that in the control group after 6 weeks of treatment.The difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 18.18%.The control group was 15.63%.There was no significant difference between the two groups(P>0.05).After 6 weeks of treatment,the social,emotional,role,physical and cognitive scores of the observation group were higher than the control group,and the difference was statistically significant(P<0.05).Conclusion:Xiaoke Jiedu Decoction combined with DCF regimen has significant effect on advanced gastric cancer,and it has high safety.It can improve T lymphocyte subsets and NK activity and improve patients′ quality of life.

关 键 词：进展期胃癌 消癌解毒方 DCF方案 生命质量 T淋巴细胞亚群 

分 类 号：R273[医药卫生—中西医结合]